In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Optimising heart failure treatment following cardiac resynchronisation therapy

Session Poster Session 2

Speaker Kasper Pryds

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : A Jorsal (Aarhus,DK), K Pryds (Aarhus,DK), J Mcmurray (Glasgow,GB), H Wiggers (Aarhus,DK), A Sommer (Aarhus,DK), JC Nielsen (Aarhus,DK), RR Nielsen (Aarhus,DK)

Authors:
A Jorsal1 , K Pryds1 , J Mcmurray2 , H Wiggers1 , A Sommer1 , JC Nielsen1 , RR Nielsen1 , 1Aarhus University Hospital, Department of Cardiology - Aarhus - Denmark , 2University of Glasgow, Institute of Cardiovascular & Medical Sciences, University of Glasgow - Glasgow - United Kingdom of Great Britain & Northern Ireland ,

Citation:

BACKGROUND: Device therapy in addition to medical treatment improves prognosis in a subset of patients with heart failure and reduced ejection fraction. However, some patients remain symptomatic or their heart failure even progresses despite cardiac resynchronization therapy (CRT). The aim of the study was to evaluate the proportion of patients who could benefit from optimization of medical therapy by using sacubitril/valsartan, ivabradine or both following CRT implantation.

METHODS: Post-hoc analysis of a single-center, double blind, controlled trial, in which, patients scheduled for CRT were randomized to empiric (n=93) or imaging-guided left ventricular lead placement (n=89). All patients underwent clinical evaluation and blood sampling at baseline and 6 months following CRT implantation. The proportion of patients meeting the indication for sacubitril/valsartan (irrespective of angiotensin-converting enzyme inhibitor or angiotensin 2 receptor blocker dosage) and/or ivabradine in current guidelines was evaluated at baseline and after 6 months.

RESULTS: Of 182 patients with an indication for CRT, 146 (80%) also had an indication for optimization of medical therapy at baseline by adding sacubitril/valsartan, ivabradine or both. Of the 179 survivors at 6 months, 136 (76%) were still symptomatic after device implantation; of these, 51 (38%) patients had an indication for optimization of medical therapy: sacubitril/valsartanin 37 (27%), ivabradine in 7 (5%), and both drugs in 7 (5%) patients. Seven (18%) patients without indication at baseline developed an indication for medical optimization 6 months after CRT implantation.

CONCLUSION: In the present study, 38%of those who remained symptomatic 6 months after CRT implantation were eligible for optimization of medical therapy with sacubitril/valsartan, ivabradine or both. Patients with CRT may benefit from systematic follow-up including evaluation of medical treatment.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are